Zabaglurant

Zabaglurant (INNTooltip International Nonproprietary Name;^[2] developmental code names HTL14242 and TMP-301) is a metabotropic glutamate mGlu₅ receptor negative allosteric modulator which is under development for the treatment of alcoholism (alcohol use disorder).^{[1][3][4][5][6]} It is taken orally.^[1] The drug was first described in the scientific literature by 2015.^[4][5][6] It was developed by Sosei Heptares, Nxera Pharma, and Tempero Bio.^[1][3] As of April 2026, the drug is in phase 2 clinical trials for alcoholism.^[1][3] It was also under development for cocaine-related disorders, other substance-related disorders, anxiety disorders, neurological disorders, and psychiatric disorders, but no recent development has been reported or development was discontinued for these indications.^[1][3] In April 2026, a phase 2 trial for alcoholism was terminated due to serious adverse events.^[1][7]

Other namesHTL14242; HTL-14242; HTL-0014242; HTL0014242; Heptares 25; TMP-301; TMP301

Routes of
administrationOral^[1]

Drug classMetabotropic glutamate mGlu₅ receptor negative allosteric modulator

CAS Number

• 1644645-32-8

Quick facts Clinical data, Other names ...

Zabaglurant

Clinical data
Other names	HTL14242; HTL-14242; HTL-0014242; HTL0014242; Heptares 25; TMP-301; TMP301
Routes of administration	Oral[1]
Drug class	Metabotropic glutamate mGlu5 receptor negative allosteric modulator
Identifiers
IUPAC name 3-chloro-5-[6-(5-fluoro-2-pyridinyl)pyrimidin-4-yl]benzonitrile
CAS Number	1644645-32-8
PubChem CID	86763358
IUPHAR/BPS	14266
ChemSpider	58979975
ChEMBL	ChEMBL3603923
PDB ligand	51E (PDBe, RCSB PDB)
CompTox Dashboard (EPA)	DTXSID901352164
Chemical and physical data
Formula	C16H8ClFN4
Molar mass	310.72 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC(=NC=C1F)C2=CC(=NC=N2)C3=CC(=CC(=C3)C#N)Cl
InChI InChI=1S/C16H8ClFN4/c17-12-4-10(7-19)3-11(5-12)15-6-16(22-9-21-15)14-2-1-13(18)8-20-14/h1-6,8-9H Key:FQAXDSVNYVVQSE-UHFFFAOYSA-N

Close